Experience

Adelphi Values has an experienced global team of qualitative researchers, health economists, statisticians, creative scientists, clinicians and strategists with industry experience, who truly understand the need to develop evidence and communicate value throughout the product lifecycle.

Below is a selection of our projects, presented according to therapeutic or strategic/methodological area. It is not exhaustive, and we would be happy to provide further information on request.

Idiopathic pulmonary fibrosis

Landscape economic outcomes data analysis in idiopathic pulmonary fibrosis
Assistance with a Delphi panel and consensus statement on idiopathic pulmonary fibrosis

Immune thrombocytopenic purpura

Analysis and reporting on immune thrombocytopenic purpura
Caregiver interviews to support content validity of an ObsRO in a paediatric population with chronic immune thrombocytopenic purpura
Palatability and acceptability of a treatment in paediatric populations with chronic immune thrombocytopenic purpura
Development of a scoring algorithm for an acceptability and palatability questionnaire in chronic immune thrombocytopenic purpura
Literature review and qualitative research to support the content validation of the immune thrombocytopenia quality of life index

Immunology

Biosimilar payer communications in immunology
Development of a payer value deck in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
Payer value slides for a varicella vaccine
Payer value slides for immunology biosimilars
Payer value slide deck in muscle relaxation management
Payer value deck for an MMR and varicella vaccine
Payer focused value communication on rheumatoid arthritis
Payer material development for vaccines in hepatitis A, rotavirus gastroenteritis (RVGE), shingles, varicella and pneumococcal disease
Payer evidence dossier for a new psoriasis treatment
Payer value proposition in rheumatoid arthritis
Update to payer materials in rheumatoid arthritis
Communications package in hereditary angioedema
Patient support programme, payer communication tool and briefing pack in immunology
Frequently asked questions deck in juvenile idiopathic arthritis
Frequently asked questions to support the introduction of a new biosimilar in immunology
Frequently asked questions for biosimilar policy in immunology
Frequently asked questions on an immunology biosimilar for rheumatoid arthritis
Workshop and FAQ development in immunology in ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis
Literature and content searches for global value dossiers in dermatology and immunology
Structured literature review for allergy immunotherapy, including medication adherence compared to other treatments
Strategic literature review and gap analysis in systemic lupus erythematosus and lupus nephritis
Communication of a literature review on systemic lupus erythematosus and lupus nephritis
Literature review of unmet need in rheumatoid arthritis
Literature review and update to budget impact model in an immunology biosimilar
Targeted literature review in psoriatic arthritis patients with concomitant moderate to severe psoriasis
Health economics training and model training in immunology
Interactive model in immunology
Economic workshop in immunology
Economic evaluation of a workplace influenza vaccination in Russia
Total Brand FAQ deck and Total Brand Workshop in rheumatoid arthritis, prostate-specific antigen (PsA), psoriasis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis
Updates to a US budget impact model for an immunology biosimilar
AMCP dossier, budget impact model and global value dossier development in immunology
Update for a core value dossier in uveitis
Early global value dossiers for a new monoclonal antibody in Crohn’s disease and psoriasis
Global value dossiers and budget impact models for biosimilars in ankylosing spondylitis, Crohn’s disease, inflammatory bowel disease, osteoarthritis, psoriasis and rheumatoid arthritis
Update to an AMCP dossier for an immunology biosimilar
Updates to a global value dossier, AMCP dossier and budget impact model on a rheumatoid arthritis biosimilar
Two competitor review decks in psoriatic arthritis and ankylosing spondylitis
Two competitor reviews in psoriatic arthritis
Competitor value story in rheumatoid arthritis
Competitor value story in psoriatic arthritis
Competitor review of two JAK inhibitors in rheumatoid arthritis
Kidney transplant pricing research
Development of launch materials in ankylosing spondylitis and psoriatic arthritis
HTA strategy in immunology (ankylosing spondylitis and psoriatic arthritis)
Payer interviews and message testing in psoriatic arthritis
Cross-therapy area value proposition alignment in immunology
Originator vs. biosimilar value proposition update in immunology
Regulatory support on SMC questions on psoriatic arthritis work
Product value insight evaluation and strategy in atopic dermatitis
Core value dossier on psoriatic arthritis
Objection handler in rheumatoid arthritis
Budget impact model on the costs of treating psoriasis
Budget impact model on a biosimilar in multiple immunology indications
Early value dossier with value message proposition in systemic sclerosis
Pricing research on kidney transplant in emerging markets
Identification of PRO measures suitable for implementation in phase III oncology and immunotherapy trials
Analysis of a PRO and resource utilization in systemic lupus erythematosus
Critical review of PRO instruments in systemic lupus erythematosus and fatigue and pain in rheumatic disease
Review of PROs in systemic sclerosis/scleroderma
Development of posters on the analysis of a PRO and resource utilization in systemic lupus erythematosus
Patient focused outcomes in amyloidosis: Exit interviews to capture the patient experience of systemic amyloidosis, treatment and clinical trial participation
Translation and linguistic validation of clinician assessments in ACEI-Angioedema
Communications on clinician assessments in ACEI-Angioedema
Measurement strategy to demonstrate efficacy of medical devices in patients with pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumour (dTGCT)
Strategic consultancy on physician attitudes and preferences regarding adult vaccinations
Regulatory support for the validation of a questionnaire for influenza vaccination
Demonstrating the value of antibiotic resistance testing software
Modification of the Eosinophilic Esophagitis Activity Index (EEsAI)

Infertility

Development of a value dossier, health economic model and literature review in an infertility biosimilar to support pricing and reimbursement submissions in 15 EU countries
Workshop on the EU price strategy for a recombinant follicle stimulating hormone used for the treatment of infertility
Conference presentation of health economic data on infertility treatment
Pricing updates in Europe for a biosimilar hormone treatment for female infertility
Advisory board with two payers to appraise an infertility product for reimbursement
Value story and communications for an infertility study
Project management for infertility manuscripts

Inflammatory bowel disease

Pre-budget impact analysis in personalised medicine (biomarkers) for inflammatory bowel diseases

Influenza

Upgrade of current model-structure and sensitivity analysis in influenza
Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
Update of a value dossier on an influenza vaccine
Cost-effectiveness analysis of an influenza vaccine
Modification of the SIR dynamic model to the SEIR model for the USA and Italy
Modelling of influenza coverage rates
Communication of influenza coverage rates within the European Union
Book chapter written on the economics of influenza
Review of influenza vaccine uptake data
Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
Economic evaluation of a workplace influenza vaccination in Russia
Communication of the economics of an influenza vaccine
Interactive model on influenza
Adaptation of an influenza vaccine model to Belgium
Positioning paper on influenza
Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
Literature research and reporting on epidemiology and the economic burden of influenza B in Japan
Modification of a SIR dynamic model to a SEIR model for the US and Italy
Dynamic model to inform internal decision making regarding pandemic influenza
Regulatory support for the validation of a questionnaire for influenza vaccination

Influenza vaccines

Economic value dossiers for influenza vaccines in a) an unprimed paediatric population and b) a primed school age population (intranasal delivery) including literature review, gap analysis and recommendations
Communications package for an influenza vaccine
Communication of the economics of an influenza vaccine
Two manuscripts on an influenza vaccine for patients at risk and patients over 65 years old in France
Review of influenza vaccine uptake data
Updating an economic model of influenza vaccination (phase 1) – update of a model in patients aged over 65 years in France and the UK
Economic evaluation of a workplace influenza vaccination in Russia
Cost-effectiveness analysis of an influenza vaccine
Adaptation of a cost effectiveness model for an influenza vaccine for Germany, Austria and Mexico
Conference poster on the cost effectiveness of adjuvant influenza vaccination in France
Adaptation of an influenza vaccine model to Belgium
Regulatory support for the validation of a questionnaire for influenza vaccination

Insomnia and sleep disorders

Survey of the impact of allergy on sleep (including literature review and HCP interviews)
Value communication support for an insomnia study
Value communication support for a systematic literature review in insomnia
Global value dossier and AMCP dossier in insomnia
Systematic literature review of real world evidence in insomnia
Literature review and report update in insomnia
Advisory panel in insomnia
Targeted literature review in Alzheimer’s disease and associated insomnia
Manuscript on a publication of a systematic literature review in insomnia
Review of PROs in insomnia
Cognitive debriefing of the daytime insomnia symptom scale and FDA support
Strategic consulting in insomnia
Validation of a primary insomnia functioning questionnaire
PRO strategy in insomnia
Manuscripts on the development and validation of the Sleep Impact Scale (SIS) in insomnia
Support on translation of the SIS in insomnia
Communications on the SIS in insomnia
Support on the adaptation of the SIS into three languages
Support on linguistic validation of the SIS in insomnia
Investigator meeting, review and presentation of slides on the Functional Outcomes of Sleep Questionnaire (FOSQ) and Work Limitation Questionnaire (WLQ)
Validation of the FOSQ in insomnia
Development of a conceptual framework and endpoint model in insomnia, plus qualitative patient interviews to confirm the validity of the conceptual framework and the psychometric validation of the final conceptual framework
Consultation on study design and interpretation of data on insomnia
Advisory panel in sleep disorders
Quality of life questionnaire in sleep disorders
Modification to the Sleep Impact Questionnaire following FDA review
Validation and linguistic adaptation of a sleep questionnaire
Linguistic validation of the Fatigue Impact Scale (FIS) into Argentinean Spanish, Austrian German, South African English, Norwegian and Afrikaans
Evaluation of the potential for a satisfaction claim for sleep disorders
Development of a PRO instrument for measuring mood swings and sleep problems resulting from vasomotor symptoms during the menopause
Evaluation of existing documentation and recommendations for psychometrically validating the modified Daytime Insomnia Symptom Scale (mDISS)
Scenario model in sleep disorders
Development of a sleep measure in different conditions
Report of sleep problems in fibromyalgia
Content validation of the modified Daytime Insomnia Symptom Scale (DISS) and the Sleep Impact Questionnaire event log
Manuscript on validation and efficacy results in insomnia

Interstitial cystitis

Literature review on interstitial cystitis
Development of a PRO for interstitial cystitis
Identification of cut-points to allow a newly developed interstitial cystitis symptom PRO to be used to screen patients entering a clinical trial and to assess the psychometric properties of the interstitial cystitis
Development of a manuscript on the Painful Bladder/Interstitial Cystitis Symptom Score (PBIC-SS) questionnaire
Revision of a manuscript on the PBIC-SS questionnaire and submission to a peer-reviewed journal

Interstitial lung disease

Consulting to help inform a PRO strategy for pulmonary hypertension in interstitial lung disease (PH-ILD)
Brief literature review to inform endpoint strategy recommendations for interstitial lung disease in systemic sclerosis (SSc-ILD)

Irritable bowel syndrome

Literature review of PROs and endpoints of pain in irritable bowel syndrome (IBS)
Literature review and manuscript on IBS
Patient interviews and qualitative work on IBS
Analysis of focus group data in IBS
Productivity workshop in IBS
Focus groups in IBS
Consulting for PROs for a treatment used in IBS
Prospective outcomes study in IBS
PRO strategy in generalized anxiety disorder with functional digestive disorders / IBS
Mixed methods analysis of cognitive debriefing data in irritable bowel syndrome with constipation or chronic constipation (IBS-C/CC)
PRO dossier in IBS-C
Independent analysis, evidence saturation and report on 30 interviews in IBS-C
Development of a PRO strategy for paediatric IBS-C
Literature review in IBS-C
Manuscript based on the findings of the exit interview study of patients taking a treatment for IBS-C within a long term safety study
Exploratory analysis of PRO data to support the interpretation of change on IBS-C abdominal symptom endpoints
Development of PRO instruments assessing symptoms and health related quality of life for paediatric patients with IBS-C
Testing and cognitive debriefing interviews for a diary in paediatric symptoms of IBS-C/CC
Network meta-analysis of treatments for IBC-C/CC
Conference poster and debriefing of paediatric IBS-C
Cognitive debriefing of a PRO measure of IBS-C symptoms
Long term safety study and participation interviews in IBS-C
Consultation on a project on IBS-C
FDA meeting on IBS-C
Interviews with clinicians to understand diagnoses of paediatric IBS-C
Development and validation of a primary endpoint to support an indication in irritable bowel syndrome with diarrhoea (IBS-D)
Psychometric validation of a newly developed PRO for IBS-D
Analysis of qualitative data on IBS-D from focus groups
Psychometric validation for a newly developed PRO in IBS-D
Development of a PRO measurement dossier on IBS-D for submission to the FDA
Development of a PRO instrument assessing symptoms in paediatric patients with IBS-D
Assistance with preparations for an FDA type C meeting on IBS-D
Development and validation of a primary endpoint for an FDA submission in IBS-D
Selection of PROs for IBS-D, regulatory strategy and support
Phase II data analysis: Interim and final psychometric testing in IBS-D
Manuscript on IBS-C and IBS-D

Kidney cancer / Renal cell carcinoma

Landscape analysis for ablation in kidney cancer
Burden of disease deck in renal cell carcinoma
Market access payer value tool in renal cell carcinoma
Sensitivity analysis and budget impact model on renal cell carcinoma
Analyses of endpoints in oncology: Statistical analyses in renal cell carcinoma
Updates to a Health Impact Projection (HIP) model in locally advanced or metastatic renal cell carcinoma
Utilities analyses to support economic modelling in renal cell carcinoma
Value tool for decision making in renal cell carcinoma
e-v@luate platforms in renal cell carcinoma
Summary presentation of a workstream in renal disease
Caregiver burden in renal cell carcinoma in the EU
Scientific communication of a systematic literature review on caregiver burden in renal cell carcinoma
Budget impact model in renal cell carcinoma
Analyses of endpoints in oncology: Country-specific EQ-5D utilities in renal cell carcinoma
Clinical trial analyses to support health-related quality of life in renal cell carcinoma: Ad hoc analyses and Q&A document
Quick review of PRO measures for a phase II trial in renal cell carcinoma
General consultancy agreement to review two PRO measures in renal cell carcinoma to support labelling claims with the FDA and EMA

Kidney (renal) disease

Core value dossier for a treatment used in stages III, IV and V renal disease
Core value dossier in the treatment of secondary hyperparathyroidism associated with chronic kidney disease including end stage renal disease
Core value dossier in chronic kidney disease and end stage renal disease
Literature review of the burden of depression in hemodialysis patients (in chronic kidney disease)
Pilot utility elicitation study in end stage renal disease
Logistical costs of changing treatment in chronic kidney disease
Capturing costs when switching from one ESA to another for chronic kidney disease in UK hospital trusts
Payer research to understand potential pricing and reimbursement in polycystic kidney disease
Disease area review, burden of illness and unmet needs in heart failure (and associated renal dysfunction)
Meta-analysis of a treatment for chronic kidney disease: trials and PRO endpoints
Manuscripts and conference attendance for a treatment in chronic kidney disease
FDA meeting support in defence of PRO claims for a treatment for chronic kidney disease
Manuscript and advisory board on physical functioning in chronic kidney disease
Development of a manuscript and production of two posters on the symptoms of chronic kidney disease when treated with a specific drug
Review of a dossier in chronic kidney disease
Qualitative interviews, conceptual model and strategic consulting on autosomal dominant polycystic kidney disease (ADPKD)
Measures for use in patients with autosomal dominant polycystic kidney and liver disease: development and validation of a symptom measure and validation of a health survey
Regulatory consulting on claims with the FDA for a treatment for end stage renal disease (ESRD)
Relevance and context of information for a treatment for hyperphosphatemia in patients with chronic kidney disease
Preparation of a manuscript on the relevance of pharmacoeconomics studies in renal disease
Literature research and assessment of the appetite and activities of daily living in patients with end-stage renal disease

Kidney transplant

Kidney transplant pricing research
Pricing research on kidney transplant in emerging markets
Cost-effectiveness model for cytomegalovirus (CMV) prophylaxis in kidney transplant recipients
Healthcare resource use and statistical analysis consulting on a clinical trial for kidney transplantation

Leukaemia

Exploring physicians’ perceptions of adherence levels, reasons for non-adherence, and opinions of how to improve adherence in leukaemia patients receiving treatment
Patient satisfaction in chemotherapy for leukaemia

Acute lymphoblastic leukaemia

Support in IRB submissions and scientific dissemination in acute lymphoblastic leukaemia
Burden of refractory acute lymphoblastic leukaemia on patients and caregivers

Acute myeloid leukaemia (AML)

Global value dossier and e-v@luate platform for a treatment in AML
Global value dossier, conference poster and medical writing support in AML
Quality of life analysis in the treatment of AML
Payer evidence council value communication materials (booklet, slides and Q&A) to inform phase III trial design in AML
Cost-effectiveness analysis and budget impact analysis for a prognostic and minimal residual genetic tests for AML
Systematic literature review of healthcare resource utilisation in AML
Literature review of resource utilisation in AML
Strategic consulting on AML
Health-related quality of life in elderly patients with AML: Position paper on an AML treatment for inclusion in a value dossier
Qualitative research to understand the value of extended overall survival to AML patients

Chronic lymphocytic leukaemia (CLL)

Utility study in advanced CLL
Abstract and manuscript on utility study results in CLL
Payer evidence dossiers for treatments of CLL
Mixed treatment comparison and training meeting on a global value dossier for a treatment for CLL
Health state preference study mapping the change over the course of the CLL disease process
Conference poster on the health state preference study mapping the change over the course of the CLL disease process
Global value dossier for a treatment in CLL
Statistical analysis plans and provision of PRO support to the client for their trials of a biological therapy cancer treatment for CLL
General consultancy agreement to review PRO measures in CLL
Analysis of PRO data from the CLL registry
Manuscript on a budget impact model for a cross-indication biosimilar in CLL

Chronic myeloid leukaemia (CML)

Value dossier support in CML linking myelosuppression with quality of life impact
Value dossier support in CML linking response to utilities and additional analysis
Critical review of PRO instruments in CML
Adverse event to PRO linking in CML
Manuscript on AE-PRO linking in CML
Targeted literature review and manuscript on factors associated with adherence in CML
Development of a link between side effects and PROs in CML – a univariate approach

Literature reviews

We have a dedicated team of experts with vast experience in literature reviews and research, able to address client challenges and steer your product towards market access success. Our experience of systematic and structured literature reviews covers a wide range of therapeutic indications and topics including:

Structured literature reviews

Acne
Acromegaly
Actinic keratosis
Acute bacterial skin and skin structure infections (ABSSSI)
Acute myocardial infarction
Adrenoleukodystrophy
Alcohol dependency
Allergic rhinitis
Allergies
Alzheimer’s disease
Ankylosing spondylitis
Arthritis
Atypical haemolytic uremic syndrome (aHUS)
Asthma
Asthma COPD Overlap Syndrome (ACOS)
Benign prostatic hyperplasia
Breast cancer
Cervical cancer
Chronic obstructive pulmonary disease (COPD)
Colorectal cancer
Constipation (and chronic constipation)
Cough and cold
Crohn’s disease
Dementia
Depression
Diabetes (type 2)
Diptheria
Down’s syndrome
Dry eye
Dystrophic epidermolysis bullosa
Epilepsy
Fabry disease
Fibromyalgia
Fragile X syndrome
Gastric cancer
Gastric reflux
Glioblastoma
Glucose transporter type 1 deficiency syndrome
Group B streptococcus
Growth hormone deficiency
Haemophilia A and B
Hand eczema
Head and neck cancer
Heart disease
Hepatitis A and C
Herpes zoster/shingles
Hidradenitis suppurativa
HIV and AIDS
HPV
HRT outcomes in the menopause
Hypogonadism
Hypoparathyroidism
Idiopathic pulmonary fibrosis
Immune thrombocytopenia
Infertility
Influenza
Insomnia
Interstitial cystitis
Interstitial lung disease in systemic sclerosis (SSc-ILD)
Irritable bowel syndrome
Kidney cancer
Kidney disease / kidney failure
Leukaemia
Lipid modification
Liver cancer
Lower limb spasticity
Lung cancer (small cell and non-small cell)
Lupus (systemic lupus erythematosus and lupus nephritis)
Lymphomas
Macular degeneration
Melanoma
Migraine
Mucopolysaccharidosis I (MPS I)
Myocardial infarction
Neural tube defects
Nonalcoholic steatohepatitis (NASH)
Osteoarthritis
Osteomyelitis
Ovarian cancer
Pain (including chronic pain and trauma pain)
Parkinson’s disease
Peripheral artery disease
Peripheral diabetic neuropathy
Pertussis
Phenylketonuria
Polio
Post-herpetic neuralgia
Post-operative ileus
Prostate cancer
Psoriasis
Rabies
Retinitis pigmentosa
Retinopathy of prematurity
Rheumatoid arthritis
Schizophrenia
Sjögren’s syndrome
Smoking cessation
Stroke
Tetanus
Typhoid
Ulcerative colitis
Wheezing
Yellow fever

Systematic literature reviews

Asthma
Bipolar disorder
Chemotherapy-induced anaemia
Epilepsy
Hepatitis B
Herpes zoster/shingles
HPV
Leukaemia
Lung cancer (small cell and non-small cell)
Lymphomas
Melanoma
Post-herpetic neuralgia
Prostate cancer
Psoriasis
Psoriatic arthritis
Pulmonary arterial hypertension
Renal cell carcinoma

Liver cancer

Development of a HEOR strategy for treatment of hepatocellular cancer
Clinical trial analyses to support health-related quality of life in advanced hepatocellular carcinoma
Updates to a Health Impact Projection (HIP) model in hepatocellular carcinoma
Landscape analysis for ablation in liver cancer

Long-chain fatty acid oxidation disorders

Qualitative research to explore and support the assessment of the patient experience and impact on functioning of long-chain fatty acid oxidation disorders
Qualitative interviews on long-chain fatty acid oxidation disorders

Lower urinary tract symptoms

Cognitive debriefing interviews on the symptom assessment goal achievement questionnaire on lower urinary tract symptoms in the UK, Germany and Spain
Data analysis and communication activities on Self-Assessment Goal Achievement (SAGA) in lower urinary tract symptoms

Lung cancer

Preparation of 3 existing manuscripts on lung cancer for submission
Literature search and analysis of phase 2 vs phase 3 lung cancer studies
Literature and reimbursement review of intravenous versus subcutaneous therapies in lung cancer
Development of a pan-lung oncology treatment model
Landscape analysis for ablation in lung cancer
Patient interviews in lung cancer
Analyses of endpoints in oncology: Statistical analyses in lung cancer
Analyses of endpoints in oncology: Country-specific EQ-5D utilities in lung cancer
Analytical evidence for improvement in symptoms and quality of life in lung cancer patients on a specified treatment
Analytical evidence for improvement in symptoms and quality of life in pre and post-randomisation lung cancer patients (by age groups)
Strategic consulting, research and measurement in solid tumours
Strategic communications planning in lung cancer
Consulting for an FDA submission in lung cancer
Summary presentation of a workstream in lung cancer
Updates to a Health Impact Projection (HIP) model in extensive 1st line SCLC, locally advanced or metastatic 2nd line NSCLC, and metastatic 1st line NSCLC

Non-small cell lung cancer (NSCLC)

Global value dossier and e-v@luate platform in NSCLC
Global value dossier and e-v@luate platform in non-squamous NSCLC
Global value dossier and e-v@luate platform in advanced squamous NSCLC
Global value dossier for a treatment in metastatic NSCLC
Payer value deck and response to payer questions update in 1st line NSCLC
Updated payer value dossier deck and FAQs deck for 1st line NSCLC
Updated burden of disease decks, payer value dossier decks and FAQs decks for 1st line and 2nd line NSCLC
Societal costs, health-related quality of life systematic literature review and publications plan for NSCLC in Europe
Literature review of overall survival and bone metastases in NSCLC
Literature review to inform global market access materials in NSCLC
Structured literature review in advanced 1st line NSCLC
Systematic review and mixed treatment comparison in advanced NSCLC
Development of technical documentation and manuscript on NSCLC
Two manuscripts on the indirect comparison of the efficacy of two different therapies for NSCLC
Development of a manuscript on the cost-effectiveness of a treatment in NSCLC in Italy
Manuscript on the efficacy of three different drugs for the treatment of NSCLC
Model review of a drug used in the treatment of NSCLC
Multi-indication budget impact model in NSCLC
Adaptation of a multi-indication value-based pricing model in NSCLC to China
Value-based model in NSCLC
Update to a Belgian value-based pricing model in NSCLC
Standardisation of economic models in NSCLC
Global model update and country adaptations for a multi-indication value-based pricing (VBP) model on NSCLC
Burden of disease decks in advanced 1st line and 2nd line NSCLC
Burden of disease deck update in 1st line NSCLC
Integrated research plan in advanced melanoma and NSCLC
Value slide deck for treatment in NSCLC
Guidance documents for affiliates in treatment for NSCLC
Situational analysis report of epidermal growth factor receptor (EGFR) predictive testing in NSCLC
Communication toolkit for a lung cancer supplement
Companion diagnostics biomarker FAQs compilation deck in NSCLC
FAQs update in advanced 1st line NSCLC
FAQs deck update in 2nd line NSCLC
Payer slide decks and objection handler in NSCLC
Payer tools implementation guide in NSCLC
Payer value proposition deck update in 2nd line NSCLC
Payer value deck update in advanced 1st line NSCLC
Payer value deck and response to payer questions update in 1st line NSCLC
HTA submission support in epidermal growth factor receptor positive (EGFR+) and non-small cell lung cancer (NSCLC)
Value communication for a matching-adjusted indirect comparison (MAIC) in NSCLC
Abstract and manuscript on MAIC in NSCLC
Deep-dive trial design in NSCLC
Numerous abstracts and conference posters on NSCLC, advanced NSCLC and related treatments
Several abstracts and conference posters relating to the cost and cost effectiveness of a first-line treatment option for patients with NSCLC
Abstract and poster on progression-free survival and overall survival in patients with NSCLC
Literature review of outcomes and costs during treatment for advanced NSCLC
Literature review and consultancy on NSCLC
Manuscript on stage IIIb and IV NSCLC
Development of a measurement dossier in advanced NSCLC for the EMA
Meta-analysis and manuscript on stage IIIb and IV NSCLC
Development of posters for a MAIC in advanced NSCLC
Epidemiology evidence, patient pathway modelling and literature review in advanced NSCLC
Statistical analyses of clinical trial data (safety study) in NSCLC
Statistical analyses of clinical trial data (observational study) in NSCLC
Clinical trial analyses to support health-related quality of life in first-line NSCLC
Qualitative study on the needs and preferences of patients with advanced NSCLC for maintenance therapy
Development of an analysis plan in NSCLC for the USA and Europe
Analysis of PRO data in NSCLC
Qualitative interviews to understand the impact of NSCLC on quality of life and on caregivers and family members
EQ-5D review for an EMA measurement dossier in advanced NSCLC
Exploratory qualitative interviews in NSCLC patients to assess progression-free survival
Comparative effectiveness of two treatments for the treatment of NSCLC
Feasibility network meta-analysis comparison of two treatments for NSCLC
Exploratory analysis of the Visual Symptom Assessment Questionnaire (VSAQ) in patients who have undergone treatment for NSCLC
Utilities analyses to support economic modelling in NSCLC
Clinical trial analyses to support health-related quality of life in NSCLC
Impact of whole brain radiation therapy in patients with NSCLC with brain metastases

Small cell lung cancer (SCLC)

Global value dossier and upload to e-v@luate platform in SCLC
AMCP dossier in SCLC
Systematic literature reviews for the societal and health-related quality of life burden of SCLC
Systematic literature review and manuscript on real-world effectiveness and tolerability of treatments in SCLC
Literature review on real-world effectiveness and tolerability of treatment in SCLC
Utility study in SCLC
Development of a budget impact model in SCLC
Budget impact model in 1st line SCLC
Development of a disease conceptual model and endpoint recommendation for SCLC
Phase IV clinical trial analysis of two drugs used in the treatment of SCLC
Analysis of symptoms for a drug used to treat SCLC
Full text reports on the longitudinal analyses of a drug used to treat SCLC for EU submission
Literature and PRO strategy for SCLC
Clinical trial analyses to support health-related quality of life in SCLC
Literature review and consultancy on SCLC